Skip to main content
Premium Trial:

Request an Annual Quote

EXCLUSIVE: BioBridge Completes PIUMS Project; Partner AstraZeneca Collects First Unit

NEW YORK, Sept. 6 – BioBridge Computing has finished developing its PIUMS protein identification software and has delivered the first unit to its research partner AstraZeneca, GenomeWeb has learned.

PIUMS—or Protein Identification Using Mass Spectrometry—is a fully automated software that includes Pepex, BioBridge’s peak extraction software. The two companies have been developing the software since they first struck a deal in July to develop the product.

A spokesperson for Lund, Sweden-based BioBridge said that the PIUMS software will be launched around November and cost roughly $10,000.

“By developing a new improved scoring algorithm to existing alternatives and a reliable method for validation we have created a very fast database search tool with very high reliability,” said Jim Samuelson, who co-led the project for BioBridge.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.